Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HUM stock price vs ORCL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ORCL's multiple
Needs ORCL P/E.
Implied fair value · at HUM's multiple
Needs HUM P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
12 period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HUMANA INC · implied price per share
Bear
$238.74
Base
$269.81
Bull
$310.28
ORACLE CORP · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
UNITEDHEALTH GROUP INC
HUM vs UNH
Elevance Health, Inc.
HUM vs ELV
CVS HEALTH Corp
HUM vs CVS
Cigna Group
HUM vs CI
CENTENE CORP
HUM vs CNC
Oscar Health, Inc.
HUM vs OSCR
Microsoft Corporation
HUM vs MSFT
Amazon.com, Inc.
HUM vs AMZN
Alphabet Inc.
HUM vs GOOGL
International Business Machines Corporation
HUM vs IBM
Cisco Systems, Inc.
HUM vs CSCO
Salesforce, Inc.
HUM vs CRM
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe HUM can sustain double-digit revenue growth while gradually expanding margins from today’s 2.1% operating margin, then the stock remains attractive versus ORCL because HUM is cheaper on P/E, EV/EBITDA, and EV/Revenue despite the weaker current profitability profile.
HUM trades at 32.6x P/E versus ORCL at 56.4x, while also carrying far lower EV/EBITDA and EV/Revenue multiples, so the comparison suggests HUM is cheaper on both earnings and enterprise-value bases. The model’s implied price of $554.53 versus the current $320.88 points to 72.8% upside, but that gap should be interpreted cautiously because ORCL multiple is very rich and the valuation range is wide.
Supporting Metrics
